• Stable Recurring Cash Flow
• Growing Subscriber Base
• Stable Base And Recurring Cash Flow – Approximately $6.25 million per year.
Market Leadership
Among the top 3 private cord bloods in 5 key markets (Singapore, Hong Kong, India, Indonesia and the Philippines)
• Proven Track Record
• Importance of Cord Blood Storage – NEARLY 80 DISEASES ARE TREATED WITH STEM CELLS TODAY. (Various kinds of cancer blood disorders & other congenitial diseases)
Cordlife Singapore’S New Facility
1. Increase Capacity Of Up To 650,000 Cord Blood Units. (Enable economies of scale)
2. Long Term Lock-In Of Fixed Costs. (Stave off pressure on margins)
3. Plan to Rent Out Excess Capacity. (Generate potential income)
Industry Outlook (Key Demand Driver)
• Birth Rates
• Rising Affluence
• Increase Awareness & Acceptance
• Favourable Government Policies
• Rising Penetration Rates In Developing Markets
•
Recent Developments In The News In Singapore
On January 21, 2013, the government unveiled policies to boost fertility and birth rates
The $2 billion Marriage & Parenthood Package 2013 is up from the $1.6 billion package in 2008
Aims to increase Total Fertility Rate (“TFR”) to 1.4 or 1.5 over the next few years from 1.2 in 2011
One of the key initiatives is support for medical costs related to conception and delivery
An increase of $2,000 per birth in the Baby Bonus cash gift up to the fourth child
A Medisave account of $3,000 for every Singaporean baby
An extension of six years for the CDA (until the child turns 12)
An increase in the co-funding of the Assisted Reproduction Technology treatments from the current 50 per
cent to 75 per cent.
Other incentives
Enhanced maternity protection for pregnant employees
Introduction of one-week paternity leave
Parenthood Priority Scheme – sets aside 30% to 50% of new flats for first-timer couples who have young children or are expecting one.
Market is pricing in potential growth of Cordlife. It is still trading at lower PE than the more establish Health-care stocks.
So far 4000 lots done at $1.10 & above.